Momenta Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Momenta Pharmaceuticals's estimated annual revenue is currently $75M per year.
- Momenta Pharmaceuticals's estimated revenue per employee is $903,614
- Momenta Pharmaceuticals's total funding is $39.5M.
Employee Data
- Momenta Pharmaceuticals has 83 Employees.
- Momenta Pharmaceuticals grew their employee count by 11% last year.
Momenta Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Momenta Pharmaceuticals?
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars (polysaccharides) for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. We are also utilizing our ability to sequence, or analyze the molecular structure of, sugars to create technology-enabled generic versions of complex sugar-based products. Our most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox®, a widely prescribed low molecular weight heparin, or LMWH. Our novel product candidates include M118, a LMWH for the treatment of acute coronary syndromes that has been designed to possess specific biological attributes as well as a technology that has been designed to use specific sugar sequences to improve the non-invasive delivery of drugs such as therapeutic proteins.
keywords:N/A
$39.5M
Total Funding
83
Number of Employees
$75M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Momenta Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial and Business Officer | Reveal Email/Phone |
2 | Sr. Manager Finance | Reveal Email/Phone |
3 | Director,Biostatistician | Reveal Email/Phone |
4 | Research Associate | Reveal Email/Phone |
5 | lab assistant | Reveal Email/Phone |
6 | Scientist | Reveal Email/Phone |
7 | Associate Scientist | Reveal Email/Phone |
8 | Consultant | Reveal Email/Phone |
9 | Sr. Research Associate | Reveal Email/Phone |
10 | Scientist | Reveal Email/Phone |
Momenta Pharmaceuticals News
... GlaxoSmithKline plc, HanAllBiopharma, Janssen Global Services, LLC, Leo Pharma, LG Chem, AstraZeneca, Momenta Pharmaceuticals,...
Korley has firsthand experience in entrepreneurship. Immediately prior to graduate school, he worked at Momenta Pharmaceuticals (MNTA) when it...
... acquires a failed drug from big pharma and plans to repeat the ... new biosimilar biotech companies like Momenta Pharmaceuticals,...
File this under “reversal of fortunes.” Late last Friday, Momenta Pharmaceuticals disclosed that a Pfizer plant contracted to make a generic version of a best-selling multiple sclerosis medicine was slapped with a warning letter by the US Food and Drug Administration. This means Momenta will su ...
Momenta says the co-authored paper represents a conflict of interest and asked that Woodcock excuse herself from the blood thinner approval process. The FDA says it’s aware of the complaint, but Woodcock had not removed herself from the process, the Journal said. On Tuesday, the FDA’s top med ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12M | 83 | -72% | N/A |
#2 | $7.5M | 83 | 2% | N/A |
#3 | $12.9M | 83 | -11% | N/A |
#4 | $12M | 83 | N/A | N/A |
#5 | $12.9M | 83 | 14% | N/A |